Free Trial
→ Your book is inside (From Profits Run) (Ad)tc pixel Free CERO Stock Alerts

CERo Therapeutics (CERO) Competitors

CERo Therapeutics logo
$0.02 -0.01 (-25.50%)
As of 05/5/2026 03:57 PM Eastern
Compare

CERO vs. REVB, SXTP, ALZN, VIVS, and ORGS

Should you be buying CERo Therapeutics stock or one of its competitors? The main competitors of CERo Therapeutics include Revelation Biosciences (REVB), 60 Degrees Pharmaceuticals (SXTP), Alzamend Neuro (ALZN), VivoSim Labs (VIVS), and Orgenesis (ORGS). These companies are all part of the "pharmaceutical products" industry.

How does CERo Therapeutics compare to Revelation Biosciences?

CERo Therapeutics (NASDAQ:CERO) and Revelation Biosciences (NASDAQ:REVB) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends, institutional ownership and media sentiment.

CERo Therapeutics presently has a consensus price target of $45.00, indicating a potential upside of 202,602.70%. Given CERo Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe CERo Therapeutics is more favorable than Revelation Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CERo Therapeutics
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
Revelation Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Revelation Biosciences is trading at a lower price-to-earnings ratio than CERo Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CERo TherapeuticsN/AN/A-$8.30M-$102.61N/A
Revelation BiosciencesN/AN/A-$8.91M-$62.09N/A

CERo Therapeutics has a beta of 0.21, meaning that its stock price is 79% less volatile than the S&P 500. Comparatively, Revelation Biosciences has a beta of -0.14, meaning that its stock price is 114% less volatile than the S&P 500.

CERo Therapeutics' return on equity of 0.00% beat Revelation Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
CERo TherapeuticsN/A N/A -209.40%
Revelation Biosciences N/A -134.18%-105.47%

29.6% of CERo Therapeutics shares are owned by institutional investors. Comparatively, 12.8% of Revelation Biosciences shares are owned by institutional investors. 0.4% of CERo Therapeutics shares are owned by insiders. Comparatively, 8.0% of Revelation Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, CERo Therapeutics' average media sentiment score of 0.00 equaled Revelation Biosciences'average media sentiment score.

Company Overall Sentiment
CERo Therapeutics Neutral
Revelation Biosciences Neutral

Summary

CERo Therapeutics beats Revelation Biosciences on 7 of the 10 factors compared between the two stocks.

How does CERo Therapeutics compare to 60 Degrees Pharmaceuticals?

60 Degrees Pharmaceuticals (NASDAQ:SXTP) and CERo Therapeutics (NASDAQ:CERO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

60 Degrees Pharmaceuticals presently has a consensus price target of $14.10, indicating a potential upside of 754.55%. CERo Therapeutics has a consensus price target of $45.00, indicating a potential upside of 202,602.70%. Given CERo Therapeutics' higher probable upside, analysts plainly believe CERo Therapeutics is more favorable than 60 Degrees Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
60 Degrees Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
CERo Therapeutics
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67

60 Degrees Pharmaceuticals has higher revenue and earnings than CERo Therapeutics. 60 Degrees Pharmaceuticals is trading at a lower price-to-earnings ratio than CERo Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
60 Degrees Pharmaceuticals$1.41M3.09-$7.36M-$13.88N/A
CERo TherapeuticsN/AN/A-$8.30M-$102.61N/A

60 Degrees Pharmaceuticals has a beta of 2.69, indicating that its stock price is 169% more volatile than the S&P 500. Comparatively, CERo Therapeutics has a beta of 0.21, indicating that its stock price is 79% less volatile than the S&P 500.

CERo Therapeutics has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -550.67%.

Company Net Margins Return on Equity Return on Assets
60 Degrees Pharmaceuticals-550.67% N/A -132.47%
CERo Therapeutics N/A N/A -209.40%

8.0% of 60 Degrees Pharmaceuticals shares are owned by institutional investors. Comparatively, 29.6% of CERo Therapeutics shares are owned by institutional investors. 1.7% of 60 Degrees Pharmaceuticals shares are owned by company insiders. Comparatively, 0.4% of CERo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, 60 Degrees Pharmaceuticals had 2 more articles in the media than CERo Therapeutics. MarketBeat recorded 2 mentions for 60 Degrees Pharmaceuticals and 0 mentions for CERo Therapeutics. 60 Degrees Pharmaceuticals' average media sentiment score of 0.49 beat CERo Therapeutics' score of 0.00 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
60 Degrees Pharmaceuticals Neutral
CERo Therapeutics Neutral

Summary

60 Degrees Pharmaceuticals beats CERo Therapeutics on 10 of the 14 factors compared between the two stocks.

How does CERo Therapeutics compare to Alzamend Neuro?

Alzamend Neuro (NASDAQ:ALZN) and CERo Therapeutics (NASDAQ:CERO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership, media sentiment and dividends.

49.6% of Alzamend Neuro shares are held by institutional investors. Comparatively, 29.6% of CERo Therapeutics shares are held by institutional investors. 1.4% of Alzamend Neuro shares are held by company insiders. Comparatively, 0.4% of CERo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Alzamend Neuro presently has a consensus price target of $28.00, suggesting a potential upside of 2,516.82%. CERo Therapeutics has a consensus price target of $45.00, suggesting a potential upside of 202,602.70%. Given CERo Therapeutics' higher possible upside, analysts clearly believe CERo Therapeutics is more favorable than Alzamend Neuro.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alzamend Neuro
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
CERo Therapeutics
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67

Alzamend Neuro has a beta of 0.11, indicating that its share price is 89% less volatile than the S&P 500. Comparatively, CERo Therapeutics has a beta of 0.21, indicating that its share price is 79% less volatile than the S&P 500.

Alzamend Neuro is trading at a lower price-to-earnings ratio than CERo Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alzamend NeuroN/AN/A-$4.51M-$2.16N/A
CERo TherapeuticsN/AN/A-$8.30M-$102.61N/A

CERo Therapeutics' return on equity of 0.00% beat Alzamend Neuro's return on equity.

Company Net Margins Return on Equity Return on Assets
Alzamend NeuroN/A -177.52% -140.41%
CERo Therapeutics N/A N/A -209.40%

In the previous week, Alzamend Neuro had 1 more articles in the media than CERo Therapeutics. MarketBeat recorded 1 mentions for Alzamend Neuro and 0 mentions for CERo Therapeutics. Alzamend Neuro's average media sentiment score of 0.00 equaled CERo Therapeutics'average media sentiment score.

Company Overall Sentiment
Alzamend Neuro Neutral
CERo Therapeutics Neutral

Summary

Alzamend Neuro beats CERo Therapeutics on 8 of the 12 factors compared between the two stocks.

How does CERo Therapeutics compare to VivoSim Labs?

CERo Therapeutics (NASDAQ:CERO) and VivoSim Labs (NASDAQ:VIVS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

VivoSim Labs has higher revenue and earnings than CERo Therapeutics. VivoSim Labs is trading at a lower price-to-earnings ratio than CERo Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CERo TherapeuticsN/AN/A-$8.30M-$102.61N/A
VivoSim Labs$140K26.47-$2.48M-$3.15N/A

CERo Therapeutics currently has a consensus price target of $45.00, suggesting a potential upside of 202,602.70%. Given CERo Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe CERo Therapeutics is more favorable than VivoSim Labs.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CERo Therapeutics
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
VivoSim Labs
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

29.6% of CERo Therapeutics shares are owned by institutional investors. Comparatively, 8.2% of VivoSim Labs shares are owned by institutional investors. 0.4% of CERo Therapeutics shares are owned by insiders. Comparatively, 2.5% of VivoSim Labs shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

CERo Therapeutics has a net margin of 0.00% compared to VivoSim Labs' net margin of -861.27%. CERo Therapeutics' return on equity of 0.00% beat VivoSim Labs' return on equity.

Company Net Margins Return on Equity Return on Assets
CERo TherapeuticsN/A N/A -209.40%
VivoSim Labs -861.27%-15.51%-11.31%

CERo Therapeutics has a beta of 0.21, meaning that its share price is 79% less volatile than the S&P 500. Comparatively, VivoSim Labs has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500.

In the previous week, CERo Therapeutics' average media sentiment score of 0.00 equaled VivoSim Labs'average media sentiment score.

Company Overall Sentiment
CERo Therapeutics Neutral
VivoSim Labs Neutral

Summary

CERo Therapeutics and VivoSim Labs tied by winning 6 of the 12 factors compared between the two stocks.

How does CERo Therapeutics compare to Orgenesis?

CERo Therapeutics (NASDAQ:CERO) and Orgenesis (NASDAQ:ORGS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

CERo Therapeutics has higher earnings, but lower revenue than Orgenesis. Orgenesis is trading at a lower price-to-earnings ratio than CERo Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CERo TherapeuticsN/AN/A-$8.30M-$102.61N/A
Orgenesis$662K4.65-$55.36M-$11.51N/A

CERo Therapeutics has a beta of 0.21, meaning that its share price is 79% less volatile than the S&P 500. Comparatively, Orgenesis has a beta of 3.07, meaning that its share price is 207% more volatile than the S&P 500.

CERo Therapeutics currently has a consensus price target of $45.00, suggesting a potential upside of 202,602.70%. Given CERo Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe CERo Therapeutics is more favorable than Orgenesis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CERo Therapeutics
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
Orgenesis
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

29.6% of CERo Therapeutics shares are owned by institutional investors. Comparatively, 22.6% of Orgenesis shares are owned by institutional investors. 0.4% of CERo Therapeutics shares are owned by insiders. Comparatively, 5.7% of Orgenesis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

CERo Therapeutics has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%.

Company Net Margins Return on Equity Return on Assets
CERo TherapeuticsN/A N/A -209.40%
Orgenesis -3,827.81%N/A -130.18%

In the previous week, CERo Therapeutics' average media sentiment score of 0.00 equaled Orgenesis'average media sentiment score.

Company Overall Sentiment
CERo Therapeutics Neutral
Orgenesis Neutral

Summary

CERo Therapeutics beats Orgenesis on 6 of the 11 factors compared between the two stocks.

Get CERo Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CERO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CERO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CERO vs. The Competition

Export
MetricCERo TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$817K$3.09B$6.25B$11.76B
Dividend YieldN/A1.92%2.74%5.26%
P/E Ratio0.0018.3729.2427.07
Price / SalesN/A278.22504.6873.40
Price / CashN/A55.2543.3053.90
Price / Book0.004.309.676.69
Net Income-$8.30M$72.19M$3.55B$332.64M
7 Day PerformanceN/A3.03%3.02%3.07%
1 Month PerformanceN/A5.93%5.13%7.80%
1 Year PerformanceN/A44.04%38.78%41.57%

CERo Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CERO
CERo Therapeutics
0.7298 of 5 stars		$0.02
-25.5%		$45.00
+202,602.7%		-99.9%$817KN/AN/A8
REVB
Revelation Biosciences
0.9453 of 5 stars		$1.16
+0.9%		N/A-96.9%$4.28MN/AN/A10
SXTP
60 Degrees Pharmaceuticals
1.9311 of 5 stars		$1.60
-1.2%		$14.10
+781.3%		-82.6%$4.27M$1.41MN/A3
ALZN
Alzamend Neuro
2.4012 of 5 stars		$1.10
+1.9%		$28.00
+2,445.5%		-82.5%$4.11MN/AN/A4
VIVS
VivoSim Labs
0.8727 of 5 stars		$1.49
-0.7%		N/AN/A$3.91M$142KN/A20

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CERO) was last updated on 5/6/2026 by MarketBeat.com Staff.
From Our Partners
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
I’m sounding the alarm
Meta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...
Porter & Company | Sponsoredtc pixel
How to collect $1,170/month from silver
There is a silver fund paying up to 20% in yearly distributions - no mining stocks, no options required. The s...
Investors Alley | Sponsoredtc pixel
Satellite Images Spot Potential $10 Trillion Discovery
'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...
Altimetry | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Did you miss The Dark AI Summit?
Over 55,000 people attended Jeff Brown's Dark AI Summit, where he revealed a private AI company he believes ho...
Brownstone Research | Sponsoredtc pixel
Iran War Update: Trump’s Hand-Written Letter Reveals What Comes Next
Jim Rickards has uncovered what he believes is Trump's economic plan, with a key trigger date of May 15. The F...
Paradigm Press | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel